1. Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
- Author
-
C. Belliveau, M. Barkati, G. Delouya, D. Taussky, M. C. Beauchemin, C. Lambert, L. Beaulieu, D. Beliveau-Nadeau, B. Nicolas, J. F. Carrier, E. Vigneault, and C. Ménard
- Subjects
Prostate cancer ,Stereotactic radiotherapy ,Focal brachytherapy ,Quality of life ,Magnetic resonance imaging ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background For patients with a higher burden of localized prostate cancer, radiation dose escalation with brachytherapy boosts have improved cancer control outcomes at the cost of urinary toxicity. We hypothesize that a focal approach to brachytherapy boosts targeting only grossly visualized tumor volumes (GTV) combined with stereotactic radiotherapy will improve quality of life (QoL) outcomes without compromising cancer control. Methods 150 patients with intermediate or high-risk prostate cancer will be enrolled and randomized 1:1 in a cohort multiple randomized clinical trial phase 2 design. Patients are eligible if planned for standard-of-care (SOC) high dose rate (HDR) brachytherapy boost to radiotherapy (RT) with GTVs encompassing
- Published
- 2022
- Full Text
- View/download PDF